Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.740
-0.110 (-2.86%)
At close: Dec 5, 2025, 4:00 PM EST
3.850
+0.110 (2.94%)
After-hours: Dec 5, 2025, 7:58 PM EST
Prime Medicine Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Prime Medicine stock have an average target of 9.31, with a low estimate of 4.25 and a high estimate of 18. The average target predicts an increase of 148.93% from the current stock price of 3.74.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Prime Medicine stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Hold Maintains $5 → $4.25 | Hold | Maintains | $5 → $4.25 | +13.64% | Nov 11, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $10 → $9 | Strong Buy | Maintains | $10 → $9 | +140.64% | Nov 10, 2025 |
| Citigroup | Citigroup | Hold Maintains $1.5 → $4 | Hold | Maintains | $1.5 → $4 | +6.95% | Aug 12, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +167.38% | Aug 8, 2025 |
| Citigroup | Citigroup | Strong Buy → Hold Downgrades $10 → $1.5 | Strong Buy → Hold | Downgrades | $10 → $1.5 | -59.89% | May 27, 2025 |
Financial Forecast
Revenue This Year
8.34M
from 2.98M
Increased by 179.58%
Revenue Next Year
3.00M
from 8.34M
Decreased by -64.06%
EPS This Year
-1.22
from -1.65
EPS Next Year
-0.94
from -1.22
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 37.9M | 10.5M | ||||
| Avg | 8.3M | 3.0M | ||||
| Low | 2.5M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1,171.2% | 25.9% | ||||
| Avg | 179.6% | -64.1% | ||||
| Low | -15.6% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.11 | -0.59 | ||||
| Avg | -1.22 | -0.94 | ||||
| Low | -1.42 | -1.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.